A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis
Titel:
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis
Auteur:
Danese, Silvio Rothenberg, Michael E. Lim, Jeremy J. Ding, Han Ting McBride, Jacqueline M. Chen, Yiling Dash, Ajit Mar, Jordan S. Keir, Mary Peyrin-Biroulet, Laurent Panes, Julian Colombel, Jean-Frederic Feagan, Brian Valentine, John F. Schreiber, Stefan